SCHEMBL4775232

SCHEMBL4775232

CS(=O)(=O)N(Cc1cccc(Cl)c1Cl)c1ccc(C(=O)NCc2ccc(C(F)(F)F)nc2)cc1F

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.47
DGAT2 Q96PD7 1/20 0.46
TP53 P04637 1/20 0.40
LMNA P02545 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
ITK Q08881 2/20 0.39
SCN3A Q9NY46 3/20 0.39
RORC P51449 1/20 0.39
MAPT P10636 1/20 0.39
TRPM8 Q7Z2W7 2/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
KMT2A Q03164 1/20 0.38
NAMPT P43490 1/20 0.38
P2RX7 Q99572 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4775020 0.94 GAA (0.48) GAADGAT2TP53LMNASMN1; SMN2
SCHEMBL4776605 0.92 GAA (0.47) GAADGAT2TP53LMNASMN1; SMN2
SCHEMBL4767780 0.91 ROCK2 (0.46) GAADGAT2TP53LMNASMN1; SMN2
SCHEMBL4767863 0.88 GAA (0.61) GAADGAT2LMNASMN1; SMN2MAPT
SCHEMBL4776579 0.87 GAA (0.42) GAADGAT2HTTP2RX7
SCHEMBL4776754 0.84 GAA (0.47) GAADGAT2LMNASMN1; SMN2P2RX7
SCHEMBL4768157 0.81 GAA (0.70) GAADGAT2LMNASMN1; SMN2MAPT
SCHEMBL5572197 0.81 GAA (0.56) GAALMNASMN1; SMN2HTTNPSR1
SCHEMBL4772464 0.81 GAA (0.48) GAADGAT2LMNASMN1; SMN2MAPT
SCHEMBL4776119 0.80 GAA (0.47) GAADGAT2LMNASMN1; SMN2SCN3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 GAA 466/4885DGAT2 3173/4885TP53 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.